197 related articles for article (PubMed ID: 20518075)
41. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study.
Deuter CM; Koetter I; Guenaydin I; Stuebiger N; Zierhut M
Retina; 2006 Sep; 26(7):786-91. PubMed ID: 16963852
[TBL] [Abstract][Full Text] [Related]
42. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
Zouboulis CC; Orfanos CE
Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
[TBL] [Abstract][Full Text] [Related]
43. [Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease].
Tanaka H; Sugita S; Yamada Y; Kawaguchi T; Iwanaga Y; Kamoi K; Yokota M; Takase H; Mochizuki M
Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):87-95. PubMed ID: 20187505
[TBL] [Abstract][Full Text] [Related]
44. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial.
Kötter I; Vonthein R; Zierhut M; Eckstein AK; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Stübiger N
Semin Arthritis Rheum; 2004 Apr; 33(5):311-9. PubMed ID: 15079762
[TBL] [Abstract][Full Text] [Related]
45. Low dose and dose escalating therapy of interferon alfa-2a in the treatment of refractory and sight-threatening Behçet's uveitis.
Onal S; Kazokoglu H; Koç A; Akman M; Bavbek T; Direskeneli H; Yavuz S
Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S113-4. PubMed ID: 19796551
[No Abstract] [Full Text] [Related]
46. [The use of interferon alfa-2r in the treatment of autoimmune uveitis (primary or associated with Behçet's disease)].
Sánchez Román J; Pulido Aguilera MC; Castillo Palma MJ; Ocaña Medina C; Toral Peña A; López-Checa F; Wichmann I
Rev Clin Esp; 1996 May; 196(5):293-8. PubMed ID: 8768028
[TBL] [Abstract][Full Text] [Related]
47. Treatment of ocular manifestations of Behçet's disease.
Davatchi F
Adv Exp Med Biol; 2003; 528():487-91. PubMed ID: 12918750
[No Abstract] [Full Text] [Related]
48. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease.
Georgiou S; Monastirli A; Pasmatzi E; Gartaganis S; Goerz G; Tsambaos D
J Intern Med; 1998 May; 243(5):367-72. PubMed ID: 9651559
[TBL] [Abstract][Full Text] [Related]
49. Interferon-alpha--a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement.
Kuemmerle-Deschner JB; Tzaribachev N; Deuter C; Zierhut M; Batra M; Koetter I
Rheumatology (Oxford); 2008 Jul; 47(7):1051-3. PubMed ID: 18492711
[TBL] [Abstract][Full Text] [Related]
50. Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study.
Hamuryudan V; Ozyazgan Y; Fresko Y; Mat C; Yurdakul S; Yazici H
Isr Med Assoc J; 2002 Nov; 4(11 Suppl):928-30. PubMed ID: 12455182
[TBL] [Abstract][Full Text] [Related]
51. Interferon alfa-2a in the treatment of Behçet's disease.
Azizlerli G; Sarica R; Köse A; Ovül C; Kavala M; Kayabali M; Erkan F; Kural Z
Dermatology; 1996; 192(3):239-41. PubMed ID: 8726638
[TBL] [Abstract][Full Text] [Related]
52. Erosive arthritis and posterior uveitis in Behçet's disease: treatment with interferon alpha and interferon gamma.
Kötter I; Dürk H; Eckstein A; Zierhut M; Fierlbeck G; Saal JG
Clin Exp Rheumatol; 1996; 14(3):313-5. PubMed ID: 8809448
[TBL] [Abstract][Full Text] [Related]
53. Epileptic seizures as the sole manifestation of neuro-Behçet's disease: complete control under interferon-alpha treatment.
Chroni E; Monastirli A; Polychronopoulos P; Pasmatzi E; Georgiou S; Vryzaki E; Tsambaos D
Seizure; 2008 Dec; 17(8):744-7. PubMed ID: 18562217
[TBL] [Abstract][Full Text] [Related]
54. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial.
Demiroglu H; Ozcebe OI; Barista I; Dündar S; Eldem B
Lancet; 2000 Feb; 355(9204):605-9. PubMed ID: 10696980
[TBL] [Abstract][Full Text] [Related]
55. Long-term therapy with low dose cyclosporin A in ocular Behçet's disease.
Ozdal PC; Ortaç S; Taskintuna I; Firat E
Doc Ophthalmol; 2002 Nov; 105(3):301-12. PubMed ID: 12539855
[TBL] [Abstract][Full Text] [Related]
56. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study.
Alpsoy E; Durusoy C; Yilmaz E; Ozgurel Y; Ermis O; Yazar S; Basaran E
Arch Dermatol; 2002 Apr; 138(4):467-71. PubMed ID: 11939808
[TBL] [Abstract][Full Text] [Related]
57. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease.
Whitcup SM; Salvo EC; Nussenblatt RB
Am J Ophthalmol; 1994 Jul; 118(1):39-45. PubMed ID: 8023874
[TBL] [Abstract][Full Text] [Related]
58. Low-dose interferon alfa-2a therapy in severe uveitis associated with Behçet disease.
Onal S; Kazokoglu H; Direskeneli H; Yavuz S
Am J Ophthalmol; 2009 Jun; 147(6):1109-10; author reply 1110. PubMed ID: 19463552
[No Abstract] [Full Text] [Related]
59. [Treatment of skin symptoms of Behçet's disease with low dose cyclosporin A].
Iiyoshi E; Takahashi Y; Sasaki T; Nakajima H
Nihon Hifuka Gakkai Zasshi; 1989 Jul; 99(8):877-81. PubMed ID: 2585781
[TBL] [Abstract][Full Text] [Related]
60. [Adamantiades-Behçet disease. Therapeutic administration of systemic recombinant interferon-alpha-2a].
Zouboulis CC; Treudler R; Orfanos CE
Hautarzt; 1993 Jul; 44(7):440-5. PubMed ID: 8365878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
